XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 80 filers reported holding XENON PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,249,000 | +16.3% | 69,800 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,074,000 | +24.7% | 69,800 | -10.3% | 0.00% | 0.0% |
| Q3 2020 | $861,000 | -12.1% | 77,788 | -0.4% | 0.00% | 0.0% |
| Q2 2020 | $979,000 | +73.3% | 78,107 | +56.7% | 0.00% | 0.0% |
| Q1 2020 | $565,000 | -26.4% | 49,855 | -14.9% | 0.00% | 0.0% |
| Q4 2019 | $768,000 | +36.9% | 58,555 | -5.9% | 0.00% | 0.0% |
| Q3 2019 | $561,000 | +1.4% | 62,255 | +11.0% | 0.00% | 0.0% |
| Q2 2019 | $553,000 | -1.1% | 56,105 | +2.0% | 0.00% | 0.0% |
| Q1 2019 | $559,000 | +61.1% | 55,000 | 0.0% | 0.00% | – |
| Q4 2018 | $347,000 | -52.2% | 55,000 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $726,000 | +43.5% | 55,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $506,000 | +87.4% | 55,000 | 0.0% | 0.00% | – |
| Q1 2018 | $270,000 | +74.2% | 55,000 | 0.0% | 0.00% | – |
| Q4 2017 | $155,000 | -4.3% | 55,000 | 0.0% | 0.00% | – |
| Q3 2017 | $162,000 | -6.4% | 55,000 | 0.0% | 0.00% | – |
| Q2 2017 | $173,000 | -21.4% | 55,000 | 0.0% | 0.00% | – |
| Q1 2017 | $220,000 | -48.1% | 55,000 | 0.0% | 0.00% | -100.0% |
| Q4 2016 | $424,000 | – | 55,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |